Stryker is making its move into soft-tissue surgical robotics. The medical technology giant announced on October 12, 2026, that it will make an approximately $400 million (£300 million) preferred equity investment in Cambridge, UK-based CMR Surgical, become the exclusive US sales agent for its Versius robot, and secure an exclusive option to acquire the entire company in the future. The deal sets up a direct challenge to Intuitive Surgical's long-dominant da Vinci franchise in the world's largest healthcare market.

The Deal Terms

According to the joint announcement, the investment is intended to support future innovation and the global commercialisation of the Versius portfolio. The key terms include:

  • Roughly $400 million in preferred equity from Stryker, subject to regulatory approvals and customary closing conditions
  • An exclusive option for Stryker to acquire 100% of CMR Surgical's outstanding equity, on terms that have not been publicly detailed
  • Exclusive US sales agent rights for Stryker covering the Versius portfolio
  • CMR retains leadership of product development and commercialisation in markets outside the United States

Andy Pierce, Stryker's Group President for MedSurg and Neurotechnology, will join CMR's board. Neither company disclosed what percentage of CMR the investment represents, and no closing date has been given.

What Versius Brings

Founded in 2014, CMR Surgical has built Versius around a modular architecture, with separate robotic arms designed to fit into existing operating room layouts rather than requiring a dedicated suite. The companies say the system supports a broad range of soft-tissue procedures and offers flexibility across procedure types, surgeon access and care settings.

Versius first won approval in Europe in 2019 and has since been authorised in multiple territories across the Asia-Pacific region and the Americas. Its current robot, Versius Plus, received FDA clearance in December 2025 for gallbladder removal, according to Medical Device Network's coverage via Yahoo Finance. In Europe and other markets, the system is cleared for additional procedures including colorectal and urologic surgery.

That narrow initial US clearance helps explain why the partnership matters: CMR has the technology and international track record, but lacks the hospital relationships and salesforce needed to scale quickly in America. Stryker has both.

Strategic Logic for Stryker

Stryker is already a heavyweight in surgical robotics, but its strength lies in orthopaedics. GlobalData figures cited by Medical Device Network put Stryker's 2025 share of the US orthopaedic robotic systems market at 75.5%, far ahead of Zimmer Biomet at 10.4%. Across all robotic surgical systems, Stryker ranked second in the US with 19.5%, behind Intuitive at 48.8%.

General surgery is where Intuitive's grip is tightest, with an estimated 80.6% of the US general surgery robotic systems market. That is the segment Versius targets.

Pierce described soft-tissue robotics as "a high-growth adjacency" and characterised the alliance as a thoughtful and disciplined entry, noting it builds on Stryker's existing strengths in endoscopy, visualisation and enabling technologies. CMR chief executive Massimiliano Colella called the deal "a significant milestone for CMR," saying Stryker's scale and customer relationships create a major growth opportunity in the United States.

Investors reacted calmly. Stryker shares rose about 1% in morning trading after the announcement, according to Medical Device Network.

A Structured Path to Acquisition

The preferred equity plus buyout option structure is a familiar playbook in medtech. It lets Stryker test commercial traction for Versius in the US before committing to a full acquisition, while giving CMR capital and distribution immediately. If US adoption accelerates and the FDA clears more procedures, Stryker holds the right to bring the company fully in-house. If not, its exposure is capped.

For CMR, the deal also offers its backers a clearer route to value. Andrew Williamson of Cambridge Innovation Capital, CMR's largest UK investor, described the investment as a UK manufacturing and technology success story.

Why It Matters

Surgical robots are one of the most commercially proven corners of the robotics industry, yet the soft-tissue segment has remained heavily concentrated around a single vendor. A credible second option backed by a company of Stryker's size could intensify competition on price, service models and system flexibility, all of which matter to hospitals weighing large capital purchases.

The deal also reflects a wider pattern across robotics in 2026: established industrial and healthcare players are partnering with, or buying, specialist robotics firms rather than building every capability internally. For hospitals, more competition could mean broader access to minimally invasive robotic procedures. For Intuitive, it signals that its most important market is about to get more contested.

What to Watch

The next milestones include regulatory approval and closing of the investment, the pace of additional FDA clearances for Versius Plus, and any disclosure of the stake size and buyout terms. Early US hospital placements under Stryker's sales organisation will offer the first real signal of whether the partnership can dent Intuitive's lead.

Sources